SCHEMBL15908265

SCHEMBL15908265

CC(C)(C)c1ccc2c(c1)OCN2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.40
ALDH1A1 P00352 3/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP19A1 P11511 1/20 0.33
KIF11 P52732 8/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
ADRA1D P25100 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
KCNH2 Q12809 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13532011 0.85 ALDH1A1 (0.40) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL760553 0.82 TRPV1 (0.55) TRPV1ALDH1A1HPGDHSD17B10ADRA2A
SCHEMBL15828682 0.80 TRPV1 (0.47) TRPV1ALDH1A1HSD17B10KIF11ADRA2A
SCHEMBL25926813 0.76 CYP19A1 (0.42) ALDH1A1HPGDCYP19A1MEN1MAPT
SCHEMBL8469595 0.75 ALDH1A1 (0.47) ALDH1A1HPGDHSD17B10CYP19A1ADRA2A
SCHEMBL15828683 0.74 BRD4 (0.37) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL22792664 0.73 ALDH1A1 (0.31) ALDH1A1HSD17B10GAAMAPT
SCHEMBL762348 0.73 TRPV1 (0.58) TRPV1KIF11MAPTPKM
SCHEMBL12931832 0.73 TRPV1 (0.41) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL22169027 0.73 CYP19A1 (0.48) ALDH1A1HPGDALOX15HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 TRPV1 3866/4885ALDH1A1 4277/4885HPGD 3073/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 TRPV1 3866/4885ALDH1A1 4277/4885HPGD 3073/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 TRPV1 3866/4885ALDH1A1 4277/4885HPGD 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.